Biotech ETFs Hovering Around a 52-Week: Here's Why
Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the rebound just starting?
Zacks·3h ago
More News
Biotech ETF (BBC) Hits New 52-Week High
Biotech ETF BBC just hit a 52-week high on regulatory tailwinds, Fed rate-cut hopes, and cheaper valuations.
Zacks·2d ago
Biotech ETFs Bounce Back in 2025: Here's Why
Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.
Zacks·10d ago
Trade War or Not, Specific Industry ETFs Are in Sweet Spots
Trade war jitters rise, but ETFs like MSOS, SILJ, SGDJ, BBC, WISE & CTEX shine on solid fundamentals, offering either safe havens or growth potential.
Zacks·14d ago
The Zacks Analyst Blog Highlights BWET, GOEX, SLVP, LIT and BBC
BWET, GOEX, SLVP, LIT and BBC topped last week's ETF winners as tech strength, Fed cut hopes and commodity moves drove gains.
Zacks·2mo ago
Best-Performing ETFs of Last Week
BWET, GOEX, SLVP, LIT and BBC stood out as last week's best-performing ETFs, driven by sector-specific fundamentals, safe-haven demand and Fed rate cut hopes.
Zacks·2mo ago
CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Mode
The company reported revenue of €14.5 million for the fourth quarter, representing a decrease of €8.1 million from the corresponding period of 2023, and below an analyst estimate of €20.58, according to FinChat data.